Home
/ Nativa
/ Competitors

Nativa Competitors and Similar CompaniesClear all

Nativa's competitors and similar companies include Samil Pharmaceutical, Green-Swan Pharmaceuticals, Carlsbad Technology and Sopharma Trading.

	Nativa Nativa is a company that distributes medicines.	Samil Pharmaceutical Samil Pharmaceutical (삼일제약주) is a manufacturer and supplier of medical devices and pharmaceutical products.	Green-Swan Pharmaceuticals Green-Swan Pharmaceuticals is a company that manufactures and distributes drugs, medical devices, and dietary supplements.	Carlsbad Technology Carlsbad Technology is a company developing and distributing generics, supplements, and medical devices.	Sopharma Trading Sopharma Trading operates as a trading company in the healthcare sector in Bulgaria.
Founding Date	Founding Date 1999	Founding Date 1947	Founding Date 1997	Founding Date 1990	Founding Date 2006
Type	Type Private	Type Public	Type Private	Type Subsidiary	Type Public
Tags	Tags Healthcare distribution medical devices pharma supplements	Tags Healthcare distribution drug development medical devices pharma supplements	Tags Healthcare distribution drug development medical devices pharma supplements	Tags Healthcare distribution medical devices pharma supplements	Tags Healthcare distribution medical devices pharma supplements
Locations	Locations Centurion, ZA HQ	Locations KR HQ	Locations CZ HQ	Locations Carlsbad, US HQ	Locations Sofia, BG HQ
Employees	Employees N/A	Employees 586	Employees 72	Employees 413% increase	Employees 749
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ₩219.7b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) лв2.3b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods ₩138.8b (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods лв2b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit ₩81.3b (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit лв305m (FY, 2025)
Net income	Net income N/A	Net income (₩5.6b) (FY, 2024)	Net income N/A	Net income N/A	Net income лв58.4m (FY, 2025)